COVID-19 vaccine effectiveness
(Randomized evidence)

Analyses are updated every Friday

Methods

Variants of concern

RCTs

Vaccine types

Overall effectiveness and safety of all vaccines vs placebo (Last update:2021-11-19)

Trials reports under extraction

In addition to the below included trials, we have included and presently extracting 2 new vaccine randomized trials:

Toledo-Romani ME, medrxiv, 2021(2) Safety and Immunogenicity of anti-SARS CoV-2 vaccine SOBERANA 02 in homologous or heterologous scheme
Walter E, N Engl J Med, 2021 Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age

Description of primary studies

In this table, we report the main characteristics of the COVID-19 vaccine candidates from RCTs identified, in addition to the overall risk of bias assessment.

For phase 1-2 studies, we report on the general charecteristics and assess the risk of Bias for safety outcomes only. Results from phase1-2 studies are included in forest plots for the chosen vaccine dose and schedule.

The evidence synthesis with forest plots and summary of findings table and evidence profile are provided for the chosen vaccine schedule with results collected from relevant phase 1, 2 and 3 studies.

Results for each vaccine comparisons are the summary of evidence from the latest study report results.

Trial Type Comparisons Design Participants Sample size Overall risk
of bias
Highest assessment
Full description
Intervention 1 Intervention 2
NCT04510207, ChiCTR2000034780
Sinopharm - China National Biotec Group Company Limited
Al Kaabi N, JAMA, 2021

Full text
Commentary
Commentary
Inactivated virus

WIV04

HBO2

Placebo

RCT
Phase 3
Healthy adults free of known COVID-19 or HIV infection at 3 centres in United Arab Emirates and Bahrain N=40411
Some concerns
Details

Full description

NCT04649151
ModernaTX
Ali K, N Engl J Med, 2021

Full text
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 2-3
Healthy adolescents in 26 centers in the USA N=3732
Some concerns
Details

Full description

NCT04568031
AstraZeneca+University of Oxford
Asano M, Int J Infect Dis, 2021

Full text
(21)00818-3/fulltextCommentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Adults with or without mild, well-controlled co-morbidities seronegative and PCR negative to SARS-CoV-2 at 5 centres in Japan N=256
Low
Details

Full description

EudraCT 2021-002348-57
Pfizer-BioNTech; Moderna; Oxford-AstraZeneca
Bonelli M, medRxiv, 2021

Full text
Commentary
Commentary
Non replicating viral vector

ChAdOx1 booster

BNT or mRNA booster

RCT
*
Adults under current rituximab therapy who did not develop humoral response against SARS-CoV-2 after their standard vaccination with Biontech/Pfizer or Moderna in a single center in Austria N=60
Some concerns
Details

Full description

NCT04860739, EudraCT2021-001978-37
Pfizer/BioNTech+Fosun Pharma
Borobia A M, Lancet, 2021

Full text
Commentary
RNA based vaccine

ChAd/BNT

No vaccine

RCT
Phase 2
Healthy, or clinically stable, adults (aged ≥18 and ≤60) that were SARS-COV-2 infection free and who had received a prime ChAdOx1-S vaccination between 8 and 12 weeks before the screening visit in 5 centers in Spain. N=676
Some concerns
Details

Full description

NCT04651790
Sinovac Research and Development Co., Ltd
Bueno S, Clin Infect Dis, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Adult healthcare workers with no history of confirmed symptomatic SARS-CoV-2 infection who were in contact with possible or confirmed cases of COVID-19 in 8 sites in Chile. N=434
Some concerns
Details

Full description

NCT04495933
The University of Queensland; Syneos Health; CSIRO Manufacturing; Seqirus; Coalition for Epidemic Preparedness Innovations
Chappell K, Lancet, 2021

Full text
Commentary
Protein subunit

SARS-CoV-2 Sclamp 5-mcg D

SARS-CoV-2 Sclamp 15-mcg

SARS-CoV-2 Sclamp 45-mcg

SARS-CoV-2 Sclamp 45-mcg

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 at one center in Australia. N=120
Some concerns
Details

Full description

NCT04412538
Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAMS).
Che Y, Clin Infect Dis, 2020

Full text
Commentary
Inactivated virus

KMS-1 100 EU D0/14

KMS-1 150 EU D0/14

KMS-1 100 EU D0/28

KMS-1 150 EU D0/28

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in two centres in China N=750
Some concerns
Details

Full description

ISRCTN89951424
AstraZeneca+University of Oxford
Clemens S, Nat. Commun., 2021

Full text
Commentary
Commentary
Non replicating viral vector

ChAdOx1

MenACWY

RCT
Phase 3
Adults that were SARS-CoV-2 seronegative and with no history of COVID-19 in six centers in Brazil. N=10416
Some concerns
Details

Full description

NCT04611802
Novavax
Dunkle L M, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Healthy adults in 113 sites in the USA and 6 in Mexico N=29949
Some concerns
Details

Full description

NCT04470427
ModernaTX
El Sahly HM, N Engl J Med, 2021
COVE

Full text
Commentary
RNA based vaccine

mRNA-1273

Placebo

RCT
Phase 3
Healthy adults with no known history of SARS-CoV-2 infection in 99 centers in the US N=30415
Some concerns
Details

Full description

NCT04471519
Bharat Biotech
Ella R(1), Lancet Infect Dis, 2021
Updated

Full text
Commentary
Inactivated virus

BBV152 3mcg + Algel-IMDG

BBV152

BBV152

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/PCR negative adults in 11 centres in India N=375
Some concerns
Details

Full description

NCT04471519
Bharat Biotech
Ella R(2), Lancet Infect Dis, 2021

Full text
Commentary
; Commentary
Inactivated virus

BBV152

3mcg BBV152 + Algel-IMDG

RCT
Phase 2
Healthy adults (<65 yo) and children (≥12 yo)volunteers, SARS-CoV-2 infection-free in 9 centres in India N=380
Some concerns
Details

Full description

NCT04641481
Bharat Biotech
Ella R(3), medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

BBV152

Placebo

RCT
Phase 3
Adults with no history of SARS-CoV-2 infection who were healthy or had stable chronic medical conditions at 25 centers in India N=25778
Some concerns
Details

Full description

NCT04400838
AstraZeneca + University of Oxford
Emary K, Lancet, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

MenACWY

RCT
Phase 2-3
Adults seronegative at baseline enrolled at 19 study sites in UK N=10673
Some concerns
Details

Full description

NCT04508075 ; INA-WXFM0YX
Sinovac Research and Development Co., Ltd
Fadlyana E, Vaccine, 2021

Full text
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthy adults aged 18 - 59 years, seropositive and seronegative, at a single center in Indonesia N=1620
Some concerns
Details

Full description

NCT04516746
AstraZeneca+University of Oxford
Falsey A, N Engl J Med, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 3
Adults (22% over 65 years) at high risk for exposure to SARS-CoV-2 and populations at increased risk for Covid-19 complications at 88 sites in USA, Chile, and Peru N=32451
Some concerns
Details

Full description

ChiCTR2100041705, ChiCTR2100041706
Sinopharm + China National Biotec Group + Beijing Institute of Biological Products
Feng Y, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

BBIBP-CorV D0/14

BBIBP-CorV D0/21

BBIBP-CorV D0/28

RCT
*
Healthy adults from high-risk occupational population at a single center in China N=809
Some concerns
Details

Full description

NCT04324606; ISRCTN15281137
AstraZeneca+University of Oxford
Folegatti PM, Lancet, 2020
COV001

Full text
Commentary
; Commentary
(20)31611-1/fulltext
Non replicating viral vector

ChAdOx1 SD

MenACWY

RCT
Phase 1 - 2
Healthy adults with no history of laboratory confirmed SARS-CoV-2 infection or of COVID-19-like symptoms in five centres in the UK N=1067
Low
Details

Full description

NCT04368988
Novavax
Formica N, PLoS Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

NVX-CoV2373 5mcg D0

25mcg NVX-CoV2373 D0/D21

25mcg NVX-CoV2373 D0

Placebo

RCT
Phase 2
Healthy adults (stable comorbidities and confirmed COVID-19 with mild symptoms permitted) aged 18-84 years at 17 centers in Australia and USA N=1288
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech+Fosun Pharma
Frenck R, N Engl J Med, 2021

Full text
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 3
Adolescents aged 12 to 15 years with no previous Covid-19 diagnosis or SARS-CoV-2 infection in 29 centers in the USA N=2264
Some concerns
Details

Full description

NCT04636697
Medicago Inc
Gobeil P, medRxiv, 2021

Full text
Full text
Commentary
Commentary
Virus-Like particle (VLP)

CoVLP 3.75mcg +AS03

Placebo

RCT
Phase 2
Healthy adults, adults with comorbidities, non-institutionalized older adults (seronegative and seropositive) in multiple centers in Canada and the USA N=753 N/A

Full description

NCT04537208
Sanofi Pasteur, GlaxoSmithKline
Goepfert P, Lancet, 2021

Full text
Commentary
Protein subunit

CoV2 preS dTM LD + AFO3

CoV2 preS dTM LD + ASO3

CoV2 preS dTM HD + AFO3

CoV2 preS dTM HD + ASO3

CoV2 preS dTM HD

Placebo

RCT
Phase 1-2
Health adults aged 18 years and older and SARS-CoV-2 infection-free in 10 centres in the USA. N=271
Some concerns
Details

Full description

ChiCTR2000031809
Sinopharm-Wuhan
Guo W, EClinicalMedicine, 2021

Full text
Commentary
Inactivated virus

Inactivate 5 mcg D0/21

Placebo

RCT
Phase 1-2
Healthy adults with no history of COVID-19 at 5 centers in China. N=1120
Some concerns
Details

Full description

NCT04885907
ModernaTX
Hall VG, N Engl J Med, 2021

Full text
Commentary
Commentary
RNA based vaccine

mRNA-1273 boost

mRNA-1273/Placebo

RCT
Phase 4
Solid organ transplant recipients with no previous diagnosis of COVID-19 who has previously received two doses of mRNA-1273 at a single center in Canada N=120
Some concerns
Details

Full description

NCT04551547
Sinovac Research and Development Co., Ltd
Han B, SSRN, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 1.5 mcg D0/28

Placebo

CoronaVac

RCT
Phase 1/2
Healthy children and adolescents aged 3-17 years with no history of SARS-CoV-2 infection in a single centre in China. N=552
Low
Details

Full description

NCT04583995; EudraCT 2020-004123-16
Novavax
Heath P, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 3
Adults 18 to 84 years old who were healthy or had stable chronic medical conditions with no history of COVID-19 at 33 centres in the UK. N=15187
Some concerns
Details

Full description

NCT04695652
Medigen Vaccine Biologics+Dynavax+NIAID
Hsieh SM, Lancet, 2021

Full text
Commentary
Protein subunit

MVC-COV1901

Placebo

RCT
Phase 2
Healthy adults and adults with stable pre-existing medical conditions at 11 centers in Taiwan. N=3854
Some concerns
Details

Full description

NCT04368988
Novavax
Keech C, N Engl J Med, 2020

Full text
Commentary
Protein subunit

25mcg NVX-D0/21

NVX-CoV2373

25mcg NVX/M1-D0/21

25mcg NVX/M1+Placebo-D0/2

Placebo

RCT
Phase 1
Healthy adult volunteers, SARS-CoV-2 infection-free and no history of SARS-CoV-2 infection in two centres in Australia. N=134
Some concerns
Details

Full description

NCT04652102; EudraCT 2020-003998-22
CureVac AG
Kremsner P, SSRN, 2021
HERALD

Full text
Commentary
Commentary
RNA based vaccine

CVnCoV

Placebo

RCT
Phase 2-3
Adults with no history of COVID-19 in 47 centers in Belgium, Germany, The Netherlands, Spain, Argentina, Colombia, Dominican Republic, Mexico, Panama and Peru N=39529
Some concerns
Details

Full description

CTRI/2020/08/027170
Serum Institute of India/AstraZeneca+University of Oxford
Kulkarni P, SSRN, 2021

Full text
Commentary
Commentary
Non replicating viral vector

SII-ChAdOx1

ChAdOx1

RCT
Phase 2-3
Adults (seronegative and seropositive) without a history of COVID and not immunocompromised at 14 centers in India N=401
Some concerns
Details

Full description

CTRI/2020/08/027170
Serum Institute of India/AstraZeneca+University of Oxford
Kulkarni P(1), SSRN, 2021

Full text
Commentary
Commentary
Non replicating viral vector

SII-ChAdOx1

Placebo

RCT
Phase 2-3
Adults (seronegative and seropositive)without a history of COVID and not immunocompromised at 14 centers in India N=1200
Some concerns
Details

Full description

NCT04671017; ISRCTN 82411169
Valneva Austria GmbH + National Institute for Health Research, UK
Lazarus R, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

VL A2001 3AU

VL A2001 3AU

VL A2001 35AU

VL A2001 7AU

RCT
Phase 1-2
Healthy adult volunteers aged 18-55 at 4 centers in the UK N=153
Some concerns
Details

Full description

ChiCTR2000034825 ; NCT04523571
BioNTech RNA Pharmaceuticals
Li J, Nature Medicine, 2021

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg

BNT162b1 10 mcg

RCT
Phase 1
Healthy young adults between 18 and 55 years of age, and older adults between 65 and 85 that were SARS-COVID-2 infection-free at a single center in China. N=144
Low
Details

Full description

NCT04892459
Sinovac Research and Development Co Ltd + CanSino Biological Inc / Beijing Institute of Biotechnology
Li J(1), medRxiv, 2021

Full text
Commentary
Commentary
Non replicating viral vector

CoronaVac/boost Ad5

CoronaVac/boost

RCT
Phase 4
Healthy adults with no previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection at one centre in China N=200
Some concerns
Details

Full description

NCT04892459
Sinovac Research and Development Co Ltd + CanSino Biological Inc / Beijing Institute of Biotechnology
Li J(2), medRxiv, 2021

Full text
Commentary
Commentary
Non replicating viral vector

CoronaVac/Ad5

CoronaVac

RCT
Phase 4
Healthy adults with no previous clinical or virologic COVID-19 diagnosis or SARS-CoV-2 infection at one centre in China N=100
Some concerns
Details

Full description

NCT04383574
Sinovac Research and Development Co., Ltd
Li M, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 2
Healthy adults aged ≥60 years with no known history of COVID-19 or recent exposure in a single center in China. N=350
Some concerns
Details

Full description

ChiCTR2100045108
Guangdong Provincial Center for Disease Control and Prevention
Liao Y, Emerg Microbes Infec, 2021

Full text
Commentary
Protein subunit

V-01 10 mcg

V-01 25 mcg

V-01 50 mcg

Placebo

RCT
Phase 1
Healthy seronegative adults with no history of COVID-19 in a single center in China N=180
Some concerns
Details

Full description

ISRCTN69254139, EudraCT: 2020-005085-33
AstraZeneca+University of Oxford; Pfizer/BioNTech+Fosun Pharma
Liu X, Lancet, 2021
Com-COV

Full text
Commentary
RNA based vaccine

ChAd/ChAd

BNT/BNT

ChAd/BNT

BNT/ChAd

RCT
Phase 2
Adults 50 years or older with no previous SARS-CoV-2 infection, no or well-controlled mild-moderate comorbidities and HIV-negative in 8 centers in the UK N=463
Some concerns
Details

Full description

NCT04530396
Gamaleya Research Institute of Epidemiology and Microbiology
Logunov D, Lancet, 2021
RESIST

Full text
Commentary
; Commentary
; Commentary
Non replicating viral vector

GAM-COVID-VAC

Placebo

RCT
Phase 3
SARS-CoV-2- and HIV infection-free adult volunteers at 25 centers in Russia N=21977
Some concerns
Details

Full description

NCT04480957
Arcturus Therapeutics Inc.
Low J, medRxiv, 2021

Full text
Commentary
Commentary
RNA based vaccine

ARCT-021 3mcg

ARCT-021 5mcg

Placebo

RCT
Phase 2
Healthy HIV-negative adults at a single Center in Singapore. N=64
Some concerns
Details

Full description

NCT04480957
Arcturus Therapeutics Inc.
Low J, medRxiv, 2021

Full text
Commentary
Commentary
RNA based vaccine

ARCT-021 1mcg

ARCT-021 5mcg

ARCT-021 7.5mcg

ARCT-021 10mcg

Placebo

RCT
Phase 1
Healthy HIV-negative adults at a single Center in Singapore. N=42
Some concerns
Details

Full description

NCT04444674, PACTR202006922165132
AstraZeneca+University of Oxford
Madhi S, Lancet, 2021

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Adults living with HIV in 7 centers in South Africa N=104
Low
Details

Full description

NCT04444674
AstraZeneca + University of Oxford
Madhi S, N Engl J Med, 2021
COV005

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 1-2
Healthy adult volunteers that were HIV-negative and SARS-CoV-2 infection-free in 7 centres in South Africa N=2026
Some concerns
Details

Full description

NCT04642638
Inovio Pharmaceuticals
Mammen Jr M, medRxiv, 2021

Full text
Commentary
Commentary
DNA based vaccine

INO-4800 1mg D0/28

INO-4800 2mg D0/28

Placebo

RCT
Phase 2
Healthy adult volunteers SARS-CoV-2 seronegative at high risk of infection at 16 locations in the USA. N=201
Some concerns
Details

Full description

NCT04530656
West China Hospital of Sichuan University
Meng F, Signal Transduct Tar, 2021

Full text
Commentary
Protein subunit

Sf9 cells vaccine

Sf9 cells vaccine

Sf9 cells vaccine

Placebo

RCT
Phase 1
Healthy adults with no history of COVID-19 in a single centre in China N=168
Some concerns
Details

Full description

NCT04640402
West China Hospital of Sichuan University
Meng F, Signal Transduct Tar, 2021

Full text
Commentary
Protein subunit

COVID-19 vaccine (Sf9 cel

COVID-19 vaccine (Sf9 cel

COVID-19 vaccine (Sf9 cel

COVID-19 vaccine (Sf9 cel

Placebo

RCT
Phase 2
Healthy adults with no history of COVID-19 in a single centre in China N=960
Some concerns
Details

Full description

NCT04611243
Sinovac Research and Development Co., Ltd; and Pfizer/BioNTech + Fosun Pharma
Mok C K P, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac/Boost

CoronaVac/Boost BNT162b2

RCT
*
Adults that had received two doses of CoronaVac but had low immune response against SARS-CoV-2 at two centres in Hong Kong, China N=80
Some concerns
Details

Full description

NCT04683484
Nanogen Pharmaceutical Biotechnology JSC
Nguyen T, SSRN, 2021

Full text
Full text
Commentary
Commentary
Protein subunit

Nanocovax 25 mcg

Nanocovax 50 mcg

Nanocovax 75 mcg

Placebo

RCT
Phase 2
Healthy HIV-negative and seronegative adults at 2 centers in Vietnam N=560
Some concerns
Details

Full description

NCT04683484
Nanogen Pharmaceutical Biotechnology JSC
Nguyen T, SSRN, 2021

Full text
Full text
Commentary
Commentary
Protein subunit

Nanocovax 25 mcg

Nanocovax 50 mcg

Nanocovax 75 mcg

RCT
Phase 1
Healthy HIV-negative and seronegative adults at a single center in Vietnam N=60
Some concerns
Details

Full description

NCT04456595
Sinovac Research and Development Co., Ltd
Palacios R, SSRN, 2021
PROFISCOV

Full text
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthcare professionals with or without previous COVID-19 infection caring for COVID-19 patients at 16 centers in Brazil. N=12408
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Pan H, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 3mcg D0/14/42

CoronaVac 6mcg D0/14/42

Placebo

RCT
Phase 2
Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China N=150
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Pan H , medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 3mcg 0/28/56

CoronaVac 6mcg 0/28/56

Placebo

RCT
Phase 2
Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China N=150
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co Ltd
Pan H , medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 3mcg 0/28/208

CoronaVac 6mcg 0/28/208

Placebo

RCT
Phase 2
Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China N=150
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co Ltd
Pan H , medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac 3mcg 0/14/194

CoronaVac 6mcg 0/14/194

Placebo

RCT
Phase 2
Healthy adults 18-59 years that were SARS-CoV-2 infection and antibody free at a single centre in China N=150
Some concerns
Details

Full description

NCT04756323, ChiCTR2000039462
Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology
Pan HX, Chin Med J, 2021

Full text
Commentary
Inactivated virus

KCONVAC 5mcg D0/14

KCONVAC 5mcg D0/14

KCONVAC 5mcg D0/28

KCONVAC 5mcg D0/28

KCONVAC 5mcg D0/14

KCONVAC 10mcg D0/14

KCONVAC 10mcg D0/14

KCONVAC 5mcg D0/14

KCONVAC 10mcg D0/28

Placebo

Placebo

Placebo

RCT
Phase 2
Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. N=500
Low
Details

Full description

NCT04758273, ChiCTR2000038804
Shenzhen Kangtai Biological Products and Beijing Minhai Biotechnology
Pan HX, Chin Med J, 2021

Full text
Commentary
Inactivated virus

5mcg KCONVAC

10mcg KCONVAC

RCT
Phase 1
Healthy adult volunteers with no history of COVID-19 and HIV- and SARS-CoV-2 infection-free in a single centre in China. N=60
Low
Details

Full description

RPCEC00000338
Finlay Vaccine Institute
Pérez-Rodríguez S, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

FINLAY-FR-1A 25 mcg

FINLAY-FR-1A 50 mcg

FINLAY-FR-1

RCT
Phase 1
Adults, age 19-59, with no history of previous SARS-CoV-2 infection at a single center in Cuba. N=60
Low
Details

Full description

NCT04764422
The Government Pharmaceutical Organization (GPO); PATH; Dynavax
Pitisuttithum P, medRxiv, 2021

Full text
Commentary
Commentary
Inactivated virus

NDV-HXP-S 1mcg

NDV-HXP-S 1mcg + CpG1018

NDV-HXP-S 3mcg

NDV-HXP-S 3mcg + CpG1018

NDV-HXP-S 10mcg

NDV-HXP-S 1mcg

Placebo

RCT
Phase 1
Healthy adults without immunosuppression negative for SARS-CoV-2 antibodies at a single center in Thailand N=210
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech+Fosun Pharma
Polack F, N Engl J Med, 2020

Full text
Commentary
; Commentary
; Commentary
; Commentary
; Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2/3
Healthy SARS-CoV-2 DNA negative adults in multiple centres in Argentina, Brazil, Germany, South Africa, Turkey, and the USA N=43448
Some concerns
Details

Full description

NCT04412538
The Institute of Medical Biology (IMB), Chinese Academy of Medical Sciences (CAM
Pu J, Vaccine, 2021

Full text
Commentary
Inactivated virus

KMS-1 100 EU D0/14

KMS-1 100 EU D0/28

Placebo

RCT
Phase 1
Healthy adults aged 18 to 59 years, SARS-CoV-2 nucleic acid or antibodies negative in a single centre in China N=192
Some concerns
Details

Full description

NCT04405908
Clover Biopharmaceuticals, Chengdu, China
Richmond P, Lancet, 2021

Full text
Commentary
Protein subunit

SCB-2019 3 mcg

SCB-2019 3 mcg + AS03

SCB-2019 3 mcg + CpG/Alum

SCB-2019 9 mcg

SCB-2019 9 mcg + AS03

SCB-2019 9 mcg + CpG/Alum

SCB-2019 30 mcg

SCB-2019 30 mcg + AS03

SCB-2019 30 mcg + CpG/Alu

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults aged 18-75 years at one study center in Australia N=151
Low
Details

Full description

NCT04527575
EpiVac LLC; VECTOR
Ryzhikov AB, Infektsiia Immun, 2021

Full text
Commentary
Protein subunit

EpiVacCorona

Placebo

RCT
Phase 2
Healthy adult SARS-CoV-2 infection-free volunteers in a single center in Russia. N=86
Some concerns
Details

Full description

NCT04927936
Janssen Pharmaceutical; Moderna + National Institue of Allergy and Infectious Diseases (NIAID); Pfizer/BionTech + Fosun Pharma
Sablerolles R, medRxiv, 2021

Full text
Commentary
Commentary
Non replicating viral vector

Ad26.COV2.S/No boost

Ad26.COV2.S/No boost

Ad26.COV2.S/No boost

Ad26/ boost m-RNA-1273

Ad26/ boost

Ad26/ boost

Ad26/ boost

Ad26/ boost BNT162b2

Ad26/ boost m-RNA-1273

Ad26/ boost BNT162b2

Ad26/ boost m-RNA-1273

Ad26/ boost BNT162b2

RCT
Phase 3
Healthcare workers (aged 18-65 years, without severe comorbidities, and no known history of SARS-CoV-2 infection) who received a single Ad26.COV2.S primary vaccination at 4 centers in the Netherlands. N=461
Some concerns
Details

Full description

NCT04436276
Janssen Pharmaceutical Companies
Sadoff J(1), N Engl J Med, 2021
ENSEMBLE

Full text
Commentary
Non replicating viral vector

Ad26.COV2.S

Ad26.COV2.S 1x10^11vp

Placebo

RCT
Phase 1-2
Healthy SARS-CoV-2 nucleic acid negative adults 18-55 years old and elderly >65 years old in multiple centres in Belgium and the US N=810
Low
Details

Full description

NCT04505722
Janssen Pharmaceutical Companies
Sadoff J(2), N Engl J Med, 2021
ENSEMBLE

Full text
Commentary
Non replicating viral vector

Ad26.COV2.S

Placebo

RCT
Phase 3
Adults >18 years of age at 213 centers in Argentina, Brazil, Chile, Colombia, Mexico, Peru, South Africa and USA N=44325
Some concerns
Details

Full description

NCT04533399; PACTR202009726132275
Novavax
Shinde V, N Engl J Med, 2021

Full text
Commentary
Protein subunit

NVX-CoV2373

Placebo

RCT
Phase 2
HIV-negative adults (18 to 84 years) and medically stable HIV-positive adults (18 to 64 years) at 16 sites in South Africa N=4406
Some concerns
Details

Full description

ChiCTR2100045107
Institute of Biophysics, Chinese Academy of Sciences; Livzon Bio Inc.; Guangdong Provincial Centre for Disease Control and Prevention; Gaozhou Center for Disease Control and Prevention
Shu Y-J, Chin. Med. J., 2021

Full text
Commentary
Protein subunit

V-01 10 mcg

V-01 25 mcg

V-01 50 mcg

Placebo

RCT
Phase 2
Younger (18-59) and older (60+) healthy adults with no current or past SARS-CoV-2 infection (PCR and ELISA) at a single centre in China N=880
Some concerns
Details

Full description

NCT04762680
Sanofi Pasteur + GlaxoSmithKline
Sridhar S, medrxiv, 2021

Full text
Commentary
Commentary
Protein subunit

CoV2 preS dTM 15µg

CoV2 preS dTM 10µg

CoV2 preS dTM 5µg

RCT
Phase 2
Adults with and without prior SARS-CoV-2 infection and risk factors for severe disease at 20 centers in the USA and Honduras N=722
Low
Details

Full description

NCT04436276
Janssen Pharmaceutical (Johnson & Johnson)
Stephenson K, JAMA, 2021

Full text
Commentary
Commentary
Non replicating viral vector

Ad26.COV2.S

Placebo

RCT
Phase 1
Healthy adults aged 18-55 years that were SARS-CoV-2 infection-free in a single centre in USA. N=10
Low
Details

Full description

NCT04582344
Sinovac Research and Development Co., Ltd
Tanriover M, Lancet , 2021

Full text
Commentary
Commentary
Inactivated virus

CoronaVac

Placebo

RCT
Phase 3
Healthy healthcare workers and adults aged 18–59 years with no history of COVID-19 from 24 centres in Turkey N=10218
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech+Fosun Pharma
Thomas S, N Engl J Med, 2021

Full text
Commentary
Commentary
RNA based vaccine

BNT162b2

Placebo

RCT
Phase 2-3
Children (>=12Y yo), adolescentes and adults, with no history or SARS-CoV 2 infection at 152 sites in Argentina, Brazil, Germany, South Africa, Turkey and USA N=44165
Some concerns
Details

Full description

RPCEC00000354
Instituto Finlay de Vacunas
Toledo-Romani ME, medRxiv, 2021

Full text
Commentary
Commentary
Protein subunit

FINLAY-FR-2

FINLAY-FR-2-/boost FR-1

Placebo

FINLAY-FR-2

RCT
Phase 3
Adults in medically stable condition with no self-reported previous COVID-19 infection at 48 centers in Cuba N=44031
Some concerns
Details

Full description

NCT04400838
AstraZeneca + University of Oxford
Voysey M, Lancet, 2020
COV002

Full text
Commentary
Non replicating viral vector

ChAdOx1 LD/SD

ChAdOx1 SD/SD

Placebo

RCT
Phase 2/3
Healthy adults in 18 centres in the UK N=10673
Some concerns
Details

Full description

ISRCTN89951424
AstraZeneca + University of Oxford
Voysey M, Lancet, 2020
COV003

Full text
Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
Phase 3
Healthy SARS-CoV-2 serology/DNA negative adults in six centres in Brazil N=10002
Some concerns
Details

Full description

NCT04324606;ISRCTN89951424;NCT04400838;NCT04444674
AstraZeneca+University of Oxford
Voysey M, Lancet, 2021
COV001/COV002/COV003/COV005

Full text
Commentary
; Commentary
; Commentary
Non replicating viral vector

ChAdOx1

Placebo

RCT
phase 1/2/3
Adults seronegative at baseline from four studies in multiple centres in Brazil, South Africa, and the UK N=24422
Some concerns
Details

Full description

NCT04368728
Pfizer/BioNTech+Fosun Pharma
Walsh E, N Engl J Med, 2020

Full text
Commentary
RNA based vaccine

BNT162b1 10 mcg D1/21

BNT162b1 20 mcg D1/21

BNT162b1

BNT162b1 100 mcg D1/21

BNT162b2 10 mcg D1/21

BNT162b2 20 mcg D1/21

BNT162b2

BNT162b1

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in four centres in USA N=195
Low
Details

Full description

NCT04816643
Pfizer–BioNTech
Walter E, N Engl J Med, 2021
New

Full text
Commentary
RNA based vaccine

BNT162b2 10 mcg

Placebo

RCT
Phase 2-3
Children aged 5-11 years with or without stable co-morbidities with no history of COVID-19 in 81 centres in the USA, Spain, Finland, and Poland N=2285
Some concerns
Details

Full description

NCT04450004
Medicago Inc
Ward B, Nat Med, 2021

Full text
Full text
Commentary
; Commentary
Virus-Like particle (VLP)

CoVLP 3.75mcg + CpG1018

CoVLP 3.75mcg + AS03

CoVLP 7.5mcg + CpG1018

CoVLP 7.5mcg + AS03

CoVLP 15mcg + CpG1018

CoVLP 15mcg + AS03

CoVLP 3.75mcg

CoVLP 3.75mcg

CoVLP 7.5mcg

CoVLP 7.5mcg

CoVLP 15mcg

CoVLP 15mcg

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 years at 2 centers in Canada N=180
Some concerns
Details

Full description

NCT04552366
Beijing Institute of Biotechnology, Beijing, China, and CanSino Biologics
Wu S, Lancet, 2021

Full text
Commentary
Non replicating viral vector

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 2×10¹⁰ vp mu D0

Ad5-nCoV 1×10¹⁰ vp mu D0

Ad5-nCoV 5×10¹⁰ vp im D0

Ad5-nCoV 5×10¹⁰ vp im D0

Ad5-nCoV 10×10¹⁰ vp im D0

RCT
Phase 1
Adults who were HIV-negative and seronegative for SARS-CoV-2 at a single center in China N=130
Some concerns
Details

Full description

NCT04383574
Sinovac Research and Development Co., Ltd
Wu Z, Lancet Infect Dis, 2021

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 1.5mcg D0/28

CoronaVac

CoronaVac 6mcg D0/28

Placebo

RCT
Phase 1/2
Healthy adults aged 60 years and older with no history of SARS-CoV-2 infection in a single centre in China N=422
Some concerns
Details

Full description

ChiCTR2000032459
Beijing Institute of Biological Products/Sinopharm
Xia S, Lancet Infect Dis, 2020

Full text
Commentary
Inactivated virus

BBIBP-CorV 8mcg once

BBIBP-CorV 4mcg D0/14

BBIBP-CorV 4mcg D0/21

BBIBP-CorV 4mcg D0/28

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 serology negative adults 18-59 years old and ≥60 years old in a single centre in China N=448
Some concerns
Details

Full description

ChiCTR2000031809
Sinopharm-Wuhan
Xia S, JAMA, 2020

Full text
Commentary
Inactivated virus

Inactivated 5mcg-D0/21

Placebo

RCT
Phase 2
Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test N=224
Some concerns
Details

Full description

ChiCTR2000032459
Sinopharm + China Biotec Group Co + Beijing Istitute of Biological Products
Xia S , Lancet, 2021

Full text
Commentary
Inactivated virus

BBIBP-CorV 2 mcg

BBIBP-CorV 4 mcg

Adjuvant

RCT
Phase 1-2
Healthy children and adolescents aged 3 to 17 years free from SARS-CoV-2 infection and antibodies at a single centre in China N=1008
Low
Details

Full description

ChiCTR2000031809
Sinopharm-Wuhan
Xia S, JAMA, 2020

Full text
Commentary
Inactivated virus

Inactivated 2.5mcg-3doses

Inactivated 5mcg-3doses

Inactivated 10mcg-3doses

Placebo

RCT
Phase 1
Healthy adults, aged 18 to 59 years, without history ofSARS-CoV(via on-site inquiry) or SARS-CoV-2 infection (via serologicaland nucleic acid test N=96
Low
Details

Full description

NCT04466085
Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd
Yang S, Lancet, 2021

Full text
Commentary
Protein subunit

ZF2001 25 mcg 2 doses

ZF2001 50 mcg 2 doses

ZF2001 25 mcg 3 doses

ZF2001 50 mcg 3 doses

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 infection-free adults aged 18-59 at 1 center in China N=900
Low
Details

Full description

NCT04445194
Institute of Microbiology, Chinese Academy of Sciences ; Anhui Zhifei Longcom Biopharmaceutical Co., Ltd
Yang S, Lancet, 2021

Full text
Commentary
Protein subunit

ZF2001 25 mcg 3 doses

ZF2001 50 mcg 3 doses

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-59 at 2 centers in China N=50
Some concerns
Details

Full description

NCT04530357
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Zakarya K, EClinicalMedicine, 2021

Full text
(21)00358-8/fulltextCommentary
Inactivated virus

QazCovid-in D1/21

Placebo

RCT
Phase 1
Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. N=44
Some concerns
Details

Full description

NCT04530357
Research Institute for Biological Safety Problems, Rep of Kazakhstan
Zakarya K,, EClinicalMedicine, 2021

Full text
(21)00358-8/fulltextCommentary
Inactivated virus

QazCovid-in D1/21

QazCovid-in D1

RCT
Phase 2
Healthy adults with no history of COVID-19 that tested negative for SARS-CoV-2 and HIV virus at a single centre in Kazakhstan. N=200
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y(1), Lancet Infect Dis, 2020

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac 6 mcg D0/28

CoronaVac 3 mcg D0/28

CoronaVac 6 mcg D0/14

CoronaVac

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=144
Some concerns
Details

Full description

NCT04352608
Sinovac Research and Development Co., Ltd
Zhang Y(2), Lancet Infect Dis, 2020

Full text
Commentary
; Commentary
Inactivated virus

CoronaVac

CoronaVac 6 mcg D0/14

CoronaVac

CoronaVac 6 mcg D0/28

Placebo

RCT
Phase 2
Healthy SARS-CoV-2 serology/DNA negative adults in a single centre in China N=600
Some concerns
Details

Full description

NCT04523571 ; ChiCTR
Pfizer/BioNTech + Fosun Pharma
Zhu F, ResearchSquare, 2021

Full text
Commentary
; Commentary
RNA based vaccine

BNT126b1 10 mcg/0.5 ml 2-

Placebo

RCT
Phase 1
Healthy SARS-CoV-2 infection-free adults aged 18-55 and 65-85 at a single center in China N=144
Some concerns
Details

Full description

NCT04341389
CanSino Biological Inc./Beijing Institute of Biotechnology
Zhu F, Lancet, 2020

Full text
Commentary
Commentary
Non replicating viral vector

Ad5-vectored 1×10¹¹ vp

Ad5-vectored 5×10¹⁰ vp

Placebo

RCT
Phase 2
Healthy adult volunteers with HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=508
Some concerns
Details

Full description

NCT04566770
CanSino Biological Inc./Beijing Institute of Biotechnology
Zhu F (2), Clin. Infect. Dis., 2021

Full text
Commentary
Commentary
Non replicating viral vector

Ad5-vectored 3×10^10 vp

Placebo

RCT
Phase 2b
Healthy children and adolescents aged 6-17 years that were HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=150
Low
Details

Full description

NCT04566770
CanSino Biological Inc./Beijing Institute of Biotechnology
Zhu F(1), Clin Infect Dis, 2021

Full text
Commentary
Commentary
Non replicating viral vector

Ad5-vectored 5×10^10 vp

Ad5-vectored 10×10^10 vp

Placebo

RCT
Phase 2b
Healthy volunteers aged 56 years and above that were HIV-negative and SARS-CoV-2 infection-free in a single centre in China. N=250
Low
Details

Full description